<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="294">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157321</url>
  </required_header>
  <id_info>
    <org_study_id>0000039</org_study_id>
    <nct_id>NCT05157321</nct_id>
  </id_info>
  <brief_title>Repetitive Transcranial Magnetic Stimulation in Essential Tremors Patients</brief_title>
  <official_title>Effect of Repetitive Transcranial Magnetic Stimulation on Essential Tremors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al-Azhar University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Al-Azhar University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the Effect of Repetitive Transcranial Magnetic&#xD;
      Stimulation on Essential Tremors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to start of rTMS sessions, Clinical evaluation and scaling of tremors using the ET&#xD;
      rating scale (Fahn, Tolosa, Marin Tremor Rating Scale) will be employed on the participants&#xD;
      in both groups.&#xD;
&#xD;
      rTMS frequency of 1Hz will be delivered to each of the participants in both groups. Each&#xD;
      session will be administered once daily for 3 days a week for 4 weeks. 1200 pulses (30 pulses&#xD;
      per train with total 40 trains having inter-train delay of 3 seconds) per session will be&#xD;
      provided with the coil placed on both cerebellar hemispheres. rTMS frequency of 1Hz was kept&#xD;
      constant based on previous studies.&#xD;
&#xD;
      rTMS sessions will be administered by trained professionals who was kept blinded to the&#xD;
      research protocols used in the study. After completion of therapeutic programs (after 4&#xD;
      weeks), the participants will be asked to undergo post assessment of Fahn, Tolosa, Marin&#xD;
      Tremor Rating Scale at the end of last rTMS session, 1 month, 3 months later.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 10, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in severity of essential tremors</measure>
    <time_frame>1 day, 1 month, and 3 months following the end of treatment.</time_frame>
    <description>Fahn, Tolosa, Marin Tremor Rating Scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in this group will receive active repetitive transcranial magnetic stimulation sessions for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The patients in this group will receive sham repetitive transcranial magnetic stimulation sessions for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive Transcranial Magnetic Stimulation</intervention_name>
    <description>TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Repetitive Transcranial Magnetic Stimulation</intervention_name>
    <description>Sham Repetitive Transcranial Magnetic Stimulation</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient diagnosed with Essential tremors or Essential tremors plus based on the&#xD;
             movement disorders consensus criteria(appendix 1)&#xD;
&#xD;
          2. Patient should have significant residual tremors despite of using appropriate medical&#xD;
             treatment.&#xD;
&#xD;
          3. Age: patient should be above 18 years old.&#xD;
&#xD;
          4. Gender: males and females.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with history of seizures.&#xD;
&#xD;
          2. Patient receiving tremor active drugs including:&#xD;
&#xD;
               -  Central cholinergic drugs (acetylcholine chloride, muscarinic and nicotinic&#xD;
                  agonists, anticholinesterases, and aminopropranolols)&#xD;
&#xD;
               -  Central monoaminergic drugs (neuroleptics, phenylethylamines, and indoles)&#xD;
&#xD;
               -  Peripheral adrenergic drugs (lithium carbonate, amphetamine sulfate,&#xD;
                  adrenocorticosteroids, and thyroid hormone supplements)&#xD;
&#xD;
               -  Anticonvulsants (valproic acid), bronchodilators (theophylline and terbutaline&#xD;
                  sulfate)&#xD;
&#xD;
               -  Antidepressants (amitriptyline hydrochloride).&#xD;
&#xD;
          3. patients who have metal or electronic device implanted in their body such as :&#xD;
&#xD;
               -  cardiac peace maker&#xD;
&#xD;
               -  Aneurysm clips or coils&#xD;
&#xD;
               -  Stents in the neck or brain&#xD;
&#xD;
               -  Deep brain stimulators&#xD;
&#xD;
               -  Spinal cord stimulators&#xD;
&#xD;
               -  Electrodes to monitor brain activity&#xD;
&#xD;
               -  Metallic implants in ears and eyes&#xD;
&#xD;
               -  Bullet fragments in or near the head&#xD;
&#xD;
               -  Baclofen pumps&#xD;
&#xD;
               -  Other metal devices or object implanted in or near the head&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Al-Bahay M. Reda, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, Al-Azhar University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed F. Mohammed, physician</last_name>
    <phone>020142543429</phone>
    <email>dr.a.fathy2244@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmad F. El-Adawy, Lecturer</last_name>
    <phone>0201066935667</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Al-Azhar university</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Ahmed F. Mohammed, physician</last_name>
      <phone>0201142543429</phone>
      <email>dr.a.fathy2244@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 8, 2021</study_first_submitted>
  <study_first_submitted_qc>December 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 11, 2021</last_update_submitted>
  <last_update_submitted_qc>December 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al-Azhar University</investigator_affiliation>
    <investigator_full_name>Ahmed Fathy Mohammed Mohammed</investigator_full_name>
    <investigator_title>physician</investigator_title>
  </responsible_party>
  <keyword>rTMS, essential tremors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

